{"id":"W2738407951","doi":"10.1200/jco.2017.35.15_suppl.9518","title":"A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with <i>BRAF V600</i>-mutant solid tumors and melanoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; MEK inhibitor; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Melanoma; Palbociclib; Clinical endpoint; Pharmacokinetics; Pharmacology; Cancer; Phases of clinical research; Kinase; Cancer research; MAPK/ERK pathway; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004094806,0.0003035215,0.001796957,0.0002282904,0.0002975719,0.0000568679,0.0001910501,0.0001990255,0.00002112343],"category_scores_gemma":[0.001948403,0.0001953296,0.0001063065,0.0001657587,0.000500977,0.0006440294,0.00009245918,0.0009541441,9.282264e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001927022,"about_ca_system_score_gemma":0.0009849626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005054057,"about_ca_topic_score_gemma":0.0001985633,"domain_scores_codex":[0.9956332,0.0006902168,0.002124986,0.000443356,0.0007777211,0.0003304865],"domain_scores_gemma":[0.9937643,0.001001414,0.003782503,0.0003453311,0.0007577923,0.0003486023],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05393999,0.0122027,0.5625945,0.00002168789,0.0003395636,0.00023401,0.00154012,0.00001083522,0.0005446562,0.00001209576,0.00001099585,0.3685489],"study_design_scores_gemma":[0.1674493,0.1769293,0.6528105,0.0003325726,0.0002389981,0.0002335438,0.0006878505,0.0003641403,0.0002073938,0.0002470575,0.0003148188,0.0001844955],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955074,0.0002293717,0.00008583411,0.002328311,0.0003345024,0.001393553,0.000005874338,0.00001577011,0.00009942357],"genre_scores_gemma":[0.9963295,0.0001311764,0.002588615,0.0004626211,0.000370585,0.00003178025,0.000005519527,0.00004436374,0.00003580387],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3683644,"threshold_uncertainty_score":0.7965311,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1003029350503233,"score_gpt":0.4806479685953801,"score_spread":0.3803450335450568,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}